Navigation Links
Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
Date:11/12/2013

ROCKVILLE, Md., Nov. 12, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported  financial results for the three months and nine months ended September 30, 2013 and provided a business and clinical update.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"The Company reached several major milestones in the third quarter. We completed patient dosing in our Phase Ib trial to treat major depressive disorder with NSI-189, our lead small molecule compound. We also commenced a multicenter Phase II cell therapy trial with NSI-566 to treat ALS, and completed dosing of all patients in the first cohort," said Karl Johe, PhD, Neuralstem's Chairman of the Board and Chief Scientific Officer. "The dose escalation trial for NSI-189 advanced through three cohorts of eight depression patients each, with the final cohort receiving three daily doses of 40 mg for 28 days. During the coming months we will be compiling the data from this Phase I study.

"We are particularly excited to have begun our Phase II ALS dose escalation trial, treating the first cohort of three patients in the cervical region of the spinal cord. We are currently treating the second of five cohorts and hope to transplant all 15 patients by the completion of the second quarter of 2014," continued Dr. Johe. "We are pleased that principal investigator Dr. Eva Feldman, added the University of Michigan Health System, where she is Director of Research of the ALS Clinic and Director of the A. Alfred Taubman Medical Research Institute, as a second trial center. We are working towards adding a third site, Massachusetts General, in the coming months. The Phase II trial protocol calls for increased dosing and a maximum of 40 injections and up to 400,000 cells per injection, with a one-month observation period between each cohort.

"Dr. Feldman, who is also the president of the American Neu
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
11. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Decision Resources Group finds that the vascular access device market in ... India and China (BRIC) ... the size of the United States market ... faster growth as a result of strong economic expansion, improving access ... from Decision Resources Group,s coverage of the BRIC vascular access device ...
(Date:8/20/2014)... , Aug. 20, 2014 /PRNewswire-iReach/ -- A case ... collaboration between the school,s bioengineering department and the ... the Intel® Software Academic Program, UCSD,s research focuses ... the human body.  Photo - ... exhibits the work of Dr. Todd P. ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
(Date:8/19/2014)... Cellgen Diagnostics today launched ... a corporate lab for its genetic-based medical testing ... a critical component in the move from today’s ... of personalized medicine – a more predictive, preventive, ... contributions will support Cellgen’s intent to develop the ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... YORK, Dec. 10, 2010 Pfizer Inc. (NYSE: ... of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) ... regions where it is approved (the European Union, Canada ... of Thelin worldwide. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
... University researchers have moved a step closer to ... and hold other advantages over conventional lithium-ion batteries. ... display screens, smart cards, flexible electronics and biomedical ... nickel-tin nanowires perfectly encased in PMMA, a widely ...
... the world,s smallest battery its anode a single ... has been created by a team led by Sandia ... the anode,s characteristics, the tiny rechargeable, lithium-based battery was ... Center for Integrated Nanotechnologies (CINT), a Department of Energy ...
Cached Biology Technology:Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 2Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 3Better batteries from the bottom up 2World's smallest battery created at CINT nanotechnology center 2World's smallest battery created at CINT nanotechnology center 3
(Date:8/20/2014)... Feng has built upon a National Science Foundation (NSF) ... program, and synergistically complemented it with subsequent collaborative grants, ... on "big computing" for mini-drones and a $1 million ... on "big data" for the life sciences. , As ... grant, he was able to tell a much larger, ...
(Date:8/20/2014)... When a colony of honeybees grows to about 4,000 ... reproductive cycle: the building of a special type of ... team of experts from the Department of Neurobiology and ... what starts the reproductive cycle of honeybee colonies. The ... The Science of Nature . , Reproduction isn,t ...
(Date:8/20/2014)...  The second annual Biometrics UnPlugged Executive Summit, ... Florida on September 15, 2014, will ... and Strategy at Samsung, and Philippe de Raet, Vice ... this year,s event is Mobility at the Crossroads ... UnPlugged: Mobility at the Crossroads of Commerce & ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... EAST LANSING, Mich. Nitrous oxide, a potent greenhouse gas, ... century, and nitrogen in waterways is fueling part of that ... on this new study, the role of rivers and streams ... appears to be twice as high as estimated by the ...
... Christmas, BYU nutritionists are squeezing all the healthy compounds out ... their age-old health benefits. , The popular stocking stuffer is ... wanted to learn why a whole orange is better for ... of the research could be a super-supplement that captures the ...
... Fast-moving objects create blurry images in photography, and the ... tissues constantly in motion, such as the breathing lung. ... developed a method to stabilize living lung tissue for ... The method allowed the team to observe, for the ...
Cached Biology News:Waterways contribute to growth of potent greenhouse gas 2The orange in your stocking: researchers squeezing out maximum health benefits 2New imaging advance illuminates immune response in breathing lung 2New imaging advance illuminates immune response in breathing lung 3
... F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α ... containing both a double bond at ... group at C-15. Similar to 15(S)-latanoprost, ... a potential impurity in most commercial ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Nop1p/Fibrillarin (monoclonal) Nop1p/Fibrillarin was ... of bakers yeast, Saccharomyces cerevisiae (accession ... for yeast viability and is localized ... of Nop1p is fibrillarin (accession P22087) ...
... bind specifically to Fc regions of many ... conjugates are commonly used as affinity adsorbents ... from serum, hybridoma ascites fluids, tissue culture ... are also commonly used to capture immune ...
Biology Products: